Home » Stocks » CTI BioPharma

CTI BioPharma Corp. (CTIC)

Stock Price: $1.48 USD 0.03 (2.07%)
Updated Aug 5, 2020 12:45 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 150.83M
Revenue (ttm) 2.71M
Net Income (ttm) -41.39M
Shares Out 73.68M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $1.48
Previous Close $1.45
Change ($) 0.03
Change (%) 2.07%
Day's Open 1.46
Day's Range 1.44 - 1.49
Day's Volume 264,450
52-Week Range 0.62 - 1.95

More Stats

Market Cap 150.83M
Enterprise Value 77.74M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 73.68M
Float 43.47M
EPS (basic) -0.7
EPS (diluted) -0.70
FCF / Share -0.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 331,491
Short Ratio 0.30
Short % of Float 0.42%
Beta 1.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 55.76
PB Ratio 4.08
Revenue 2.71M
Operating Income -42.11M
Net Income -41.39M
Free Cash Flow -34.81M
Net Cash 73.09M
Net Cash / Share 0.72
Gross Margin 123.66%
Operating Margin -1,556.75%
Profit Margin -1,530.20%
FCF Margin -1,286.80%
ROA -28.94%
ROE -74.84%
ROIC -435.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.50*
(136.49% upside)
Low
3.00
Current: $1.48
High
4.00
Target: 3.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.3526.2925.1557.4116.1260.0834.68--0.32
Revenue Growth-87.28%4.55%-56.2%256.2%-73.17%73.24%----
Gross Profit3.3526.2924.7856.0314.1859.1834.54--0.32
Operating Income-40.71-32.90-39.52-49.16-117-86.23-41.53-101-62.19-78.40
Net Income-40.02-29.32-40.67-52.01-119-93.37-42.74-101-62.36-82.64
Shares Outstanding57.9756.0736.4527.9518.8414.8511.425.813.432.28
Earnings Per Share-0.69-0.52-1.24-1.86-6.51-6.46-4.30-19.80-35.30-64.70
Operating Cash Flow-27.82-39.82-39.30-76.68-95.20-39.55-35.83-62.78-60.46-63.13
Capital Expenditures--0.03-0.05-0.14-0.08-0.33-1.53-2.94-2.67-1.93
Free Cash Flow-27.82-39.86-39.35-76.82-95.28-39.88-37.36-65.71-63.13-65.05
Cash & Equivalents33.6767.0443.2244.0012870.9371.6450.4447.0522.65
Total Debt9.2714.0814.0219.2656.5017.3813.31-3.9628.23
Net Cash / Debt24.4052.9629.2024.7471.6953.5658.3350.4443.10-5.58
Assets46.2889.8354.8963.8414492.2993.7273.7162.2453.59
Liabilities28.3536.8938.8056.0996.7852.3637.5027.3120.7745.28
Book Value23.6958.6921.8113.3252.0341.7645.1734.5528.72-4.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CTI BioPharma Corp.
Country United States
Employees 25
CEO Adam R. Craig

Stock Information

Ticker Symbol CTIC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CTIC
IPO Date March 21, 1997

Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.